Deals Of The Week: Pfizer/NextWave, Genzyme/Alnylam, AstraZeneca/Ironwood
Executive Summary
Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.
You may also be interested in...
Abbott Ups Its Ante On ADCs With Expanded Seattle Genetics Deal
Abbott broadens its deal with Seattle Genetics in the hot space of antibody-drug conjugates just days after announcing a pipeline setback with another partner.
Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates
RNAi pioneer Alnylam is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.
Ironwood Gears Up For Phase III China Linaclotide Trial; Eyes On South America And Other Emerging Markets
Taking an unusually global perspective for a clinical-stage biotech, Ironwood Pharmaceuticals has plans to undertake clinical trials of its lead gastrointestinal drug, linaclotide, in China, Brazil and other emerging markets, then seek regional partners.